Evaluation of the safety, tolerability, and pharmacokinetics of gammaplex® 10% versus gammaplex® 5% in subjects with primary immunodeficiency

Wasserman, Richard L., Melamed, Isaac R., Stein, Mark R., Jolles, Stephen, Norton, Miranda and Moy, James N. 2017. Evaluation of the safety, tolerability, and pharmacokinetics of gammaplex® 10% versus gammaplex® 5% in subjects with primary immunodeficiency. Journal of Clinical Immunology 37 (3) , pp. 301-310. 10.1007/s10875-017-0383-9 Item availability restricted.

PDF - Published Version Restricted to Repository staff only Download (445kB)

Abstract

Purpose This phase 3, multicenter, open-label, randomized, two-period, crossover bioequivalence trial evaluated the safety, tolerability, and pharmacokinetics of intravenous immunoglobulins (IVIGs) Gammaplex 5% and Gammaplex 10% in 33 adults and 15 children with primary immunodeficiency diseases (PIDs). Methods Eligible adults received five Gammaplex 5% infusions followed by five Gammaplex 10% infusions, or vice versa, stratified by a 21- or 28-day dosing regimen. Pediatric subjects received five Gammaplex 10% infusions only. Results The primary objective, to demonstrate the bioequivalence of Gammaplex 10% and Gammaplex 5% at the 28-day dosing interval, was met based on the Gammaplex 10%/Gammaplex 5% ratio of area under the concentration versus time curve (AUC0–28) values. Throughout the study, total immunoglobulin G trough levels were well maintained, with total values generally ≥600 mg/dL (minimum level for study inclusion). At the dosing schedules and infusion rates used in this study, safety and tolerability were comparable and acceptable in adult and pediatric PID subjects treated with Gammaplex 10% and 5%. Conclusions In this study, the first direct comparison of 5% IVIG and 10% IVIG products in PID subjects, the pharmacokinetic analysis demonstrated bioequivalence of Gammaplex 10% and Gammaplex 5% at the 28-day dosing interval. The Gammaplex 10% formulation was safe and well tolerated in pediatric and adult PID subjects. Based on the results from this bridging study in PID subjects, Gammaplex 10% could be expected to have a therapeutic effect similar to the licensed Gammaplex 5%, which has demonstrated efficacy and tolerability in patients with PID and idiopathic thrombocytopenic purpura.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Springer
ISSN:	0271-9142
Date of First Compliant Deposit:	6 November 2017
Date of Acceptance:	8 March 2017
Last Modified:	02 Jun 2023 12:26
URI:	https://orca.cardiff.ac.uk/id/eprint/106265

Citation Data

Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item